Sepsis & infection

Efficacy and Safety of Ulinastatin in the Treatment of Patients with Sepsis: The ADJUST Trial

ChestPublished multicenter, randomized, double-blind, placebo-controlled trial

Authors' conclusion

In patients with sepsis, adjunctive UTI did not reduce mortality compared with placebo. Routine use of UTI for sepsis is not supported by these findings.

Study context

Population
Adult ICU patients with sepsis meeting Sepsis-3 criteria within 48 hours of admissionrandomized, 340 received intervention (safety analysis), 335 in intention-to-treat analysis
Participants
347 patients
Comparison
Adjunctive ulinastatin, compared with placebo
  • UTIn = 165
  • Placebon = 170reference
Primary endpoint
28-day all-cause mortality
Follow-up
28 days
Methodological detailsRandomization was stratified by site and septic shock
  • Randomization was stratified by site and septic shock

Primary result

As reported in the abstract

28-day all-cause mortality
Each group vs placeboAbsolute difference (95% CI)P value
UTI
0.7%(−8.4% to 9.7%)
P = 0.98
Each group vs placeboHazard ratio (95% CI)P value
UTI
1.03(0.66–1.61)
P = 0.90

Secondary outcomes

Secondary outcomes (ICU, hospital, and 90-day mortality, and ICU/hospital length of stay)

Secondary outcomes were similar in the two groups

Safety

OutcomeUTIPlaceboAbsolute difference (95% CI)P value
Adverse eventsSafety analysis56.8%42.7%14.1% (3.6%–24.6%)P = 0.009

Original publication

Efficacy and Safety of Ulinastatin in the Treatment of Patients with Sepsis: The ADJUST Trial. Chest. Published 6 November 2026. doi:10.1016/j.chest.2026.10.033

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.